ReviewBiotechnology letters2010
Micro-algae come of age as a platform for recombinant protein production.
Review in Biotechnology letters, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 300 citations in OpenAlex.
- Recombinant Protein Drugs: A 2025 Update.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Engineered microalgal extracellular vesicles for efficient doxorubicin delivery and improved therapeutic efficacy in breast cancer.Materials today. Bio · 2026Article
- Heterotrophic fermentation of a robust human defensin in Chlamydomonas reinhardtii provides a stable and potent antibacterial.Microbial cell factories · 2026Article
- Expression and Characterization of Recombinant Triple Laterosporulin in Chlamydomonas reinhardtii.Probiotics and antimicrobial proteins · 2026Article
- Microalgal colony blot: A simple and rapid method for direct detection of recombinant protein production in microalgae colonies.PloS one · 2026Article
- Metabolic Engineering of Microalgae for Biofuel Production.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Developing a media formulation to sustainFrontiers in bioengineering and biotechnology · 2025Article
- Expression of recombinant Cap antigen of porcine circovirus type 2 in the chloroplast ofFrontiers in plant science · 2025Article
- Proteomic analysis reveals molecular changes following genetic engineering in Chlamydomonas reinhardtii.BMC microbiology · 2024Article
- The synthetic future of algal genomes.Cell genomics · 2024Review
- Comparing the Ability of Secretory Signal Peptides for Heterologous Expression of Anti-Lipopolysaccharide Factor 3 inMarine drugs · 2023Article
- Natural carbon fixation and advances in synthetic engineering for redesigning and creating new fixation pathways.Journal of advanced research · 2023Review
- Site-specific gene knock-in and bacterial phytase gene expression inFrontiers in plant science · 2023Article
- Microalgal Carotenoids: Therapeutic Application and Latest Approaches to Enhance the Production.Current issues in molecular biology · 2022Review
- Mechanisms governing codon usage bias and the implications for protein expression in the chloroplast of Chlamydomonas reinhardtii.The Plant journal : for cell and molecular biology · 2022Review
- Generation of a recombinant version of a biologically active cell-permeant human HAND2 transcription factor from E. coli.Scientific reports · 2022Article
- Article
- Inertia-Acoustophoresis Hybrid Microfluidic Device for Rapid and Efficient Cell Separation.Sensors (Basel, Switzerland) · 2022Article
- Unassembled cell wall proteins form aggregates in the extracellular space of Chlamydomonas reinhardtii strain UVM4.Applied microbiology and biotechnology · 2022Article
- Oxidative stress facilitates infection of the unicellular alga Haematococcus pluvialis by the fungus Paraphysoderma sedebokerense.Biotechnology for biofuels and bioproducts · 2022Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A complete set of genetic tools is still being developed for the micro-alga Chlamydomonas reinhardtii. Yet even with this incomplete set, this photosynthetic single-celled plant has demonstrated significant promise as a platform for recombinant protein expression. In recent years, techniques have been developed that allow for robust expression of genes from both the nuclear and plastid genome. With these advances, many research groups have examined the pliability of this and other micro-algae as biological machines capable of producing recombinant peptides and proteins. This review describes recent successes in recombinant protein production in Chlamydomonas, including production of complex mammalian therapeutic proteins and monoclonal antibodies at levels sufficient for production at economic parity with existing production platforms. These advances have also shed light on the details of algal protein production at the molecular level, and provide insight into the next steps for optimizing micro-algae as a useful platform for the production of therapeutic and industrially relevant recombinant proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.